drugset / Trial / NCT02641028
A Study in a Human Laboratory Model of Smoking Behavior
RandomizedCrossoverDouble-blindTreatment
Summary
A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior.
Timeline
- Start
- 2015-12-31
- Primary completion
- 2016-09-13
- Completion
- 2016-12-31
Outcome
Missed primary endpoint
release “The trial did not achieve its objectives of improvement of CERC-501 compared to placebo on symptoms of tobacco withdrawal and smoking behaviors” avalotx.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aticaprant | Small molecule | 15 mg | Oral |
Indications
No indication recorded.